Joy Darcis

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

This study reveals an unconventional activation mechanism of the atypical GPCR ACKR3 using engineered nanobodies and cryo-EM, showing that extracellular pocket volume changes, not microswitch conformational shifts, drive receptor activity.

This study identifies GPR182/ACKR5 as a scavenger receptor for CXCL17, GPR15L, and endogenous peptides, revealing distinct binding modes and expanding its ligand repertoire beyond classical chemokines.